The Latest Breaking News from Gilead Sciences Inc

3 Stocks with Tremendous Growth Potential in 2023

Given the pace and intensity of the Fed’s monetary tightening, there’s a strong likelihood that the U.S. will enter a recession in 2023. However, amid a strong job market and resilient consumer spending, the possibility of a soft landing still stands. Given this backdrop, quality stocks Gilead Sciences (GILD), Coca-Cola…

StockNews.com · Mar 8, 2023

2 Dividend Stocks That Could Pay You for the Rest of Your Life

As the market remains volatile due to ongoing concerns about elevated inflation, prolonged rate hikes, and an impending recession, fundamentally strong dividend stocks Bristol-Myers Squibb (BMY) Gilead Sciences (GILD) might be ideal buys to ensure a stable income stream. Moreover, these stocks could be great long-term investments. Read more.

StockNews.com · Mar 7, 2023

1 Resilient Growth Stock to Buy Now and Hold Forever

Biopharmaceutical giant Gilead Sciences’ (GILD) shares have risen nearly 30% over the past year despite lingering macroeconomic challenges. Moreover, the company delivered solid growth last year and is expected to maintain its business momentum in 2023 and beyond, driven by its diversified medicines portfolio. Hence, investors could consider buying and…

StockNews.com · Mar 3, 2023

3 Genius Dividend Stocks to Buy Now and Hold Forever

While the cooling price pressures have boosted investors’ sentiments this year, inflation is still far from the Fed’s target. Moreover, with recession possibilities still not off the table, quality dividend-paying stocks Gilead Sciences (GILD), Honda Motor (HMC), and Sysco (SYY) might be ideal buys now. Also, these stocks could be…

StockNews.com · Feb 14, 2023

3 High-Value Stocks to Buy and Hold for a Lifetime

Despite showing signs of cooling, inflation is still well above the Fed’s 2% target. Moreover, January’s strong jobs report may encourage the Fed to raise interest rates even further, keeping the stock market highly volatile in the near term. Amid an uncertain macro environment, it could be wise to buy…

StockNews.com · Feb 9, 2023

1 Dividend Stock You'll Be Thankful to Own in 2023

With the market relapsing into a fresh bout of the volatility after estimate-crushing employment numbers, high dividend-yielding and fundamentally sound stock Gilead Sciences (GILD) could help investors secure a steady income stream. Read on….

StockNews.com · Feb 9, 2023

3 Must-Have Dividend Stocks for 2023

January’s robust job report is raising concerns about how long the Fed will keep interest rates high. Market experts are now expecting a higher terminal interest rate. As uncertainty clouds over, quality stocks Gilead Sciences (GILD), Valero Energy (VLO), and ARC Document (ARC) that pay stable dividends might be ideal…

StockNews.com · Feb 7, 2023

2 Stocks to Help Jump-Start Your Passive Income in 2023

Despite an inflow of positive macro data, the Fed’s hawkish stance is expected to keep the markets under pressure for the near term. With price fluctuations being the new norm, dividend-paying stocks with solid fundamentals, BHP Group (BHP) and Gilead Sciences (GILD), could help jump-start a solid stream of passive…

StockNews.com · Feb 2, 2023

These 3 Dividend Stocks Are Worth Investing In

While the better-than-expected GDP growth in the last quarter and declining inflationary pressures are raising optimism, macro uncertainties remain. With interest rate hikes expected to continue, recession possibilities cannot be ruled out. Therefore, fundamentally sound dividend-paying stocks, AbbVie (ABBV), Gilead Sciences (GILD), and Sisecam Resources (SIRE), could be worth investing…

StockNews.com · Feb 2, 2023

1 Biotech Stock to Buy in January 2023 and 1 to Sell

Amid rising demand and government investments, the biotech industry is poised to witness significant growth in the foreseeable future. Given this backdrop, quality biotech stock Gilead Sciences (GILD) might be a wise addition to your portfolio this January. However, Stoke Therapeutics (STOK) could be best avoided, given its bleak fundamentals.…

StockNews.com · Jan 25, 2023